IP Library Granted Patent US 8,367,644
Granted Patent B2
US 8,367,644 · App. 12/900,319 · Granted Feb 5, 2013

Methods and compounds useful to induce apoptosis in cancer cells

Inventors: John C. Reed (Rancho Sante Fe, CA); Maurizio Pellecchia (San Diego, CA)
Assignee: The Burnham Institute
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,367,644
App. No.
12/900,319
Granted
Feb 5, 2013
Kind
B2
Abstract

The present invention provides a method for treating cancer in a mammal comprising contacting the cancer cells with a compound which is a apogossypol, derivative.

Claims (10)

1. A method of treating cancer in a subject, comprising administering to the subject a chemosensitizing agent selected from the group consisting of gossypol, apogossypol, derivatives of apogossypol, in combination with an anticancer agent wherein said cancer is selected from lung cancer, breast cancer, prostate cancer, colorectal cancer, and leukemia.

2. The method of claim 1 wherein the derivative of aposossypol is a compound having formula (I):

wherein: each R 6 , R 8 , R 9 and R 10 is independently hydrogen, hydroxyl, —(C 1- C 6 )alkyl, —O(C 1 -C 6 )alkyl, —(C 1 -C 6 )alkylhalo, —OC(O)(C 1 -C 6 )alkyl, or halo; each R 7 is independently hydrogen, —(C 3 -C 8 )cycloalkyl, —(C 6 -C 10 )aryl, or —(C 1 -C 6 )alkyl(C 6 -C 10 )aryl; or a pharmaceutically acceptable salt thereof.

3. The method of claim 2 wherein each R 6 , R 8 , R 9 , and R 10 group is independently hydrogen, —OH, —OCH 3 , —CF 3 , —CH 3 , —OC 2 H 5 , —OC(O)CH 3 , F, Cl, or Br.

4. The method of claim 2 wherein each R 7 group is independently hydrogen, —C 2 H 5 ; -i-Pr, n-Pr, n-Bu, t-Bu, i-Bu, s-Bu, or cyclohexyl.

5. The method of claim 2 wherein each R 6 , R 8 , and R 9 , is —OC(O)CH 3 ; each R 7 is i-propyl; and each R 10 is —CH 3 .

6. The method of claim 1 wherein the chemosensitizing agent and the anticancer agent are administered at the same time.

7. The method of claim 1 wherein the chemosensitizing agent is administered prior to the anticancer agent.

8. The method of claim 1 wherein the anticancer agent is Flavopiridol, Adriamycin, Etoposide, Taxol, cisplatin or a combination thereof.

9. The method of claim 1 wherein the leukemia is acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myelogenous leukemia, or chronic myelogenous leukemia.

Assignments (5)
CONFIRMATORY LICENSE Recorded Jul 21, 2022
From: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR
Reel/Frame 060575/0305 →
CHANGE OF NAME Recorded Oct 8, 2020
From: THE BURNHAM INSTITUTE
To: BURNHAM INSTITUTE FOR MEDICAL RESEARCH
Reel/Frame 054030/0487 →
CHANGE OF NAME Recorded Oct 8, 2020
From: BURNHAM INSTITUTE FOR MEDICAL RESEARCH
To: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
Reel/Frame 054030/0815 →
CHANGE OF NAME Recorded Oct 8, 2020
From: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
To: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
Reel/Frame 054031/0281 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 10, 2011
From: REED, JOHN C.; PELLECCHIA, MAURIZIO
To: THE BURNHAM INSTITUTE
Reel/Frame 027038/0357 →
Continuity (3)
Division 10877781 · Jun 25, 2004
Provisional Application 60482886 · Jun 25, 2003
Related Publication 20110111057A1 · May 12, 2011